Zai

Zai Lab Announces Participation in March Investor Conference

Retrieved on: 
Wednesday, March 6, 2024
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Zai, HKEX

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in March 2024:

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in March 2024:
    A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and an archived replay will be available for up to 90 days following the completion of the event.

Zai Lab Announces Participation in January Investor Conference

Retrieved on: 
Tuesday, December 19, 2023
Oncology, Health, Infectious Diseases, Neurology, General Health, Pharmaceutical, Biotechnology, HKEX, Zai

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024:

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024:
    A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replay will be available for up to 90 days following the completion of the event.

Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List

Retrieved on: 
Wednesday, December 13, 2023
Neurology, Biotechnology, Pharmaceutical, Managed Care, Oncology, Health, Infectious Diseases, Health Insurance, Acetylcholine receptor, HKEX, GMG, Patient, Zai, Ovarian cancer, Niraparib, NRDL, Pharmaceutical industry

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications:

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications:
    VYVGART® (efgartigimod alfa injection) is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive;
    ZEJULA® (niraparib) is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.
  • “The initial NRDL inclusion for VYVGART is an especially important milestone for gMG patients and underscores the clinical value Zai Lab is delivering to the medical community and to patients in China,” said William Liang, Chief Commercial Officer of Zai Lab.
  • “We are pleased that we now have four products included in the NRDL, and we will continue our efforts to expand patient access to our innovative treatments, including through NRDL coverage of different indications and formulations for our commercial products.
  • We are grateful for this action by the NHSA, and we look forward to continuing to work with the NHSA to improve patient access and costs for high-quality treatments in China.”

Zai Lab Announces Participation in November Investor Conferences

Retrieved on: 
Thursday, October 26, 2023
EST, HKEX, Zai, Fireside chats, Cryptocurrency, Communications satellite

SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023:

Key Points: 
  • SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023:
    Fireside Chat: Wednesday, November 15th at 1:00 p.m. GMT
    Fireside Chat: Wednesday, November 29th at 1:45 p.m. EST
    A live webcast of the presentations will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replays will be available for up to 90 days following the completion of each event.

Zai Lab Announces Participation in February Investor Conferences

Retrieved on: 
Tuesday, January 31, 2023
Zai, Food delivery, Self storage, Life insurance

SHANGHAI and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in February 2023:

Key Points: 
  • SHANGHAI and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in February 2023:
    Webcast links of the presentations will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website.
  • The archived replay will be viewable after each of the events for 90 days.

Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Retrieved on: 
Wednesday, January 18, 2023
GIST, IV, NRDL, Patient, Bronchopneumonia, National Medical Products Administration, ABSSSI, NMPA, Zai, KIT, Pharmaceutical industry

“NHSA reimbursement will help make QINLOCK and NUZYRA available to many more patients in need across China,” said William Liang, Chief Commercial Officer, Zai Lab.

Key Points: 
  • “NHSA reimbursement will help make QINLOCK and NUZYRA available to many more patients in need across China,” said William Liang, Chief Commercial Officer, Zai Lab.
  • “NRDL inclusion also underscores the clinical value Zai Lab is delivering to the medical community and to patients in China.”
    “A key part of Zai Lab’s mission is to bring transformative medicines to patients with unmet medical needs in China and around the world,” said Josh Smiley, Chief Operating Officer, Zai Lab.
  • “The inclusion of both QINLOCK and NUZYRA in the NRDL is another opportunity for us to achieve that mission.
  • QINLOCK targets the broad spectrum of KIT and PDGFRα mutations known to drive GIST.

Zai Lab Announces Participation in January Investor Conferences

Retrieved on: 
Tuesday, December 20, 2022
Zai, Conference, Fine chemical, Life insurance, Pharmaceutical industry

SHANGHAI, China and CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that senior management from Zai Lab will participate in the following investor conferences in January 2023:

Key Points: 
  • SHANGHAI, China and CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that senior management from Zai Lab will participate in the following investor conferences in January 2023:
    Webcast link of the corporate presentation at the J.P. Morgan 41st Annual Healthcare Conference will be available under “Events & Presentations” in the Investor Relations section of Zai Lab’s website.
  • The archived replay will be viewable after the events for 30 days.

Zai Lab Announces Participation in November Investor Conferences

Retrieved on: 
Monday, October 31, 2022
Research, SAN, Patient, GLOBE, Zai, Infection, Health, Degenerative disease, NASDAQ, Conference, Pharmaceutical industry

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in November:

Key Points: 
  • SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in November:
    Panel discussions: Several sessions available beginning on November 5, 2022 through December 30, 2022
    Webcast link of Jefferies London Healthcare Conference will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • An archived replay will be available for 90 days following the event.
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world.
  • For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global .

Zai Lab Announces Participation in September Investor Conferences

Retrieved on: 
Tuesday, August 23, 2022
Patient, Lists of diseases, Zai, Infection, Research, GLOBE, Health, Degenerative disease, SAN, NASDAQ, Pharmaceutical industry

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in September:

Key Points: 
  • SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in September:
    Webcast links of the presentations will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • The archived replay will be viewable after the events for 90 days.
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world.
  • For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global .

Zai Lab Announces Upcoming Presentations at June Investor Conferences

Retrieved on: 
Tuesday, May 24, 2022
Infection, Degenerative disease, NASDAQ, SAN, Health, Zai, GLOBE, Fine chemical

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following investor conferences in June:

Key Points: 
  • SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following investor conferences in June:
    Webcast links of the conferences will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • An archived replay will be viewable after the presentation for the following 90 days.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience.
  • For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global .